Latest & greatest articles for screening

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on screening or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on screening and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for screening

161. Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines

Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines | CADTH.ca Find the information you need Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Screening Triage Tools and Management Algorithms for Adult Sepsis Patients: Clinical Utility and Guidelines Last updated: August 13 (...) , 2019 Project Number: RA1058-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical utility of screening triage tools and/or management algorithms in adult patients in the emergency department with suspected sepsis? What is the clinical utility of screening triage tools and/or management algorithms in adult inpatients with suspected sepsis? What are the evidence-based guidelines regarding the use of screening triage tools

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

162. Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Anal Cancer Screening in High Risk Populations: Clinical Effectiveness, Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Anal Cancer Screening in High Risk Populations: Clinical Effectiveness (...) , Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Last updated: September 20, 2019 Project Number: RB1400-000 Product Line: Research Type: Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical utility of anal cancer screening in high risk populations? What is the diagnostic accuracy of Pap testing for anal cancer in high risk populations? What is the cost-effectiveness of anal cancer screening in high risk populations? What are the evidence-based

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

163. Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines

Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Interventions Used to Screen for Tuberculosis: Clinical Effectiveness and Guidelines Last updated: June 24, 2019 Project Number: RA1043-000 Product Line: Research Type: Devices and Systems Report Type (...) : Reference List Result type: Report Question What is the clinical effectiveness of interventions used to screen individuals for tuberculosis? What are the evidence-based guidelines regarding the screening of individuals for tuberculosis? Key Message Twelve systematic reviews (eight with meta-analysis) were identified regarding the clinical effectivenessof interventions used to screen individuals for tuberculosis. In addition, four evidence-based guidelines were identified regarding the screening

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

164. Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines

Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines | CADTH.ca Find the information you need Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer: Diagnostic Accuracy, Cost-Effectiveness, and Guidelines Digital Tomosynthesis for the Screening and Diagnosis of Breast Cancer (...) for breast cancer diagnosis? What is the comparative clinical effectiveness of synthetic 2D mammography compared with conventional 2D digital mammography obtained with 3D digital tomosynthesis? What is the cost effectiveness of 3D digital tomosynthesis with or without 2D mammography compared with 2D mammography alone for breast cancer screening or diagnosis? What are the evidence-based guidelines regarding the use of 3D digital tomosynthesis for breast cancer screening and diagnosis? Key Message Seven

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

165. Colorectal Cancer Screening Evidence Brief

Colorectal Cancer Screening Evidence Brief 1 Age to Initiate Colorectal Cancer Screening in Average Risk Individuals: Evidence Brief, June 2019 Key Points • Colorectal cancer incidence and mortality are increasing in individuals under age 50. • Simulation models suggest there may be benefit to screening average risk patients beginning at age 45, but it is unclear if this benefit outweighs the risks of screening • Patients age 45-49 who express interest in screening should be engaged in shared (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for colon cancer • Extra vigilance for symptoms and risk factors of colon cancer (including family history in people aged 45-49) is advised given increasing colorectal cancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectal cancer. Patients not considered average risk include those

2019 Institute for Clinical Systems Improvement

166. Breast screening: breast implant guidelines

Breast screening: breast implant guidelines Breast screening: breast implant guidelines - GOV.UK GOV.UK uses cookies which are essential for the site to work. We also use non-essential cookies to help us improve government digital services. Any data collected is anonymised. By continuing to use this site, you agree to our use of cookies. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search Promotional material Breast screening: breast implant guidelines This leaflet (...) provides information about NHS breast screening for women with breast implants. Published 1 June 2010 Last updated 1 October 2019 — From: Documents If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what assistive technology you use. HTML Details Healthcare professionals can use this information to tell women about how breast implants affect screening

2019 Public Health England

167. Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02

Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods - Addendum to Commission S13-02 1 Translation of the executive summary of the addendum S16-01 Screening auf asymptomatische Bakteriurie im Rahmen der Mutterschafts-Richtlinien unter besonderer Berücksichtigung der Testmethoden – Addendum zum Auftrag S13-02 (Version 1.0; Status: 19 October 2016). Please note: This document was translated by an external (...) translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-01 Screening for asymptomatic bacteriuria within the framework of the German maternity guidelines, under special consideration of test methods – Addendum to Commission S13-02 1 Extract of addendum S16-01 Version 1.0 Screening for bacteriuria in pregnant women 19 October 2016 Institute for Quality

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

168. Screening for depression

Screening for depression 1 Translation of the key statement of the final report S16-05 Screening auf Depression (Version 1.0; Status: 27 July 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-05 Screening for depression 1 Extract of final report S16-05 Version 1.0 Screening (...) for depression 27 July 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for depression Commissioning agency: Federal Joint Committee Commission awarded on: 27 April 2016 Internal Commission No.: S16-05 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1 E-mail: berichte@iqwig.de

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

169. Screening for hepatitis C

Screening for hepatitis C 1 Translation of the key statement of the final report S16-04 Screening auf Hepatitis C (Version 1.0; Status: 19 September 2018). Please note: This document was translated by an external translator and is provided as a service by IQWiG to English-language readers. However, solely the German original text is absolutely authoritative and legally binding. Extract IQWiG Reports – Commission No. S16-04 Screening for hepatitis C 1 Extract of final report S16-04 Version 1.0 (...) Screening for hepatitis C 19 September 2018 Institute for Quality and Efficiency in Health Care (IQWiG) - i - Publishing details Publisher: Institute for Quality and Efficiency in Health Care Topic: Screening for hepatitis C Commissioning agency: Federal Joint Committee Commission awarded on: 22 September 2016 Internal Commission No.: S16-04 Address of publisher: Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen Im Mediapark 8 50670 Köln Germany Phone: +49 221 35685-0 Fax: +49 221 35685-1

2019 Institute for Quality and Efficiency in Healthcare (IQWiG)

170. Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines

Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines | CADTH.ca Find the information you need Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Dietary Priority Screening for Chronic Kidney Disease: Clinical Effectiveness and Guidelines Last updated: January 14, 2019 Project Number: RB1297-000 Product Line: Research Type (...) : Devices and Systems Report Type: Summary of Abstracts Result type: Report Question What is the clinical effectiveness of dietary/nutrition priority screening tools for in-patients and outpatients with chronic kidney disease? What are the evidence-based guidelines for the use of dietary/nutrition prioritization tools for the delivery of nutritional therapy in the chronic kidney disease setting? Key Message One non-randomized study and three evidence based guidelines were identified regarding the use

2019 Canadian Agency for Drugs and Technologies in Health - Rapid Review

171. Screening and Management of the Hyperandrogenic Adolescent

Screening and Management of the Hyperandrogenic Adolescent ACOGCOMMITTEEOPINION Number 789 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care in collaboration with committee members Jennie Yoost, MD and Ashlyn Savage, MD. Screening and Management of the Hyperandrogenic Adolescent ABSTRACT: Although androgen excess can manifest in many ways, the most common and recognizable (...) of PCOS and those of normal puberty,whichmakesthediagnosisofPCOSintheadolescentdifficult.Treatmentofacneandhirsutismshould not be withheld during the ongoing longitudinal evaluation for possible PCOS. On physical examination, body mass index, blood pressure, and signs of hyperandrogenism, such as acne and hirsutism, should be evaluated. Although guidelines differ on recommended laboratory studies, most include measurement of total testoster- one, free testosterone, or both, and screening

2019 American College of Obstetricians and Gynecologists

172. Screening for Asymptomatic Bacteriuria in Adults: US Preventive Services Task Force Recommendation Statement. Full Text available with Trip Pro

Screening for Asymptomatic Bacteriuria in Adults: US Preventive Services Task Force Recommendation Statement. Among the general adult population, women (across all ages) have the highest prevalence of asymptomatic bacteriuria, although rates increase with age among both men and women. Asymptomatic bacteriuria is present in an estimated 1% to 6% of premenopausal women and an estimated 2% to 10% of pregnant women and is associated with pyelonephritis, one of the most common nonobstetric reasons (...) for hospitalization in pregnant women. Among pregnant persons, pyelonephritis is associated with perinatal complications including septicemia, respiratory distress, low birth weight, and spontaneous preterm birth.To update its 2008 recommendation, the USPSTF commissioned a review of the evidence on potential benefits and harms of screening for and treatment of asymptomatic bacteriuria in adults, including pregnant persons.This recommendation applies to community-dwelling adults 18 years and older and pregnant

2019 JAMA

173. Syphilis Screening in Pregnancy

Syphilis Screening in Pregnancy September 2019 INTERIM GUIDELINE ON SYPHILIS SCREENING IN PREGNANCY In April 2019, the first case of congenital syphilis in British Columbia since 2013 was reported. A second case of congenital syphilis was reported in May 2019 in a stillborn delivered in January 2019. Current and past practice in BC has included screening for syphilis as part of routine care in the first trimester; historically subsequent syphilis screening has not been routinely recommended (...) unless there was concern for syphilis risk during pregnancy. There have been ongoing discussions between the BC Centre for Disease Control’s Sexually Transmitted Infections (BCCDC STI) team and expert partners and stakeholders about the best way to approach syphilis screening in pregnancy. Recent epidemiologic syphilis trends seen in BC – including increased overall rates, increased rates in females of reproductive age, along with an increasing number of infectious syphilis cases among males who

2019 British Columbia Perinatal Health Program

174. Fetal anomaly screening laboratory handbook: Down’s, Edwards’ and Patau’s syndromes

Fetal anomaly screening laboratory handbook: Down’s, Edwards’ and Patau’s syndromes Fetal anomaly screening laboratory handbook: Down’s, Edwards’ and Patau’s syndromes - GOV.UK GOV.UK uses cookies to make the site simpler. Accept cookies You’ve accepted all cookies. You can at any time. Hide Search The United Kingdom is leaving the European Union on 31 October 2019. Guidance Fetal anomaly screening laboratory handbook: Down’s, Edwards’ and Patau’s syndromes This document sets out screening (...) laboratory guidelines and recommendations for Down’s syndrome, Edwards’ syndrome and Patau’s syndrome. Published 1 January 2015 Last updated 13 September 2019 — From: Documents Ref: PHE publications gateway number: GW-691 HTML format This file may not be suitable for users of assistive technology. If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email . Please tell us what format you need. It will help us if you say what

2019 Public Health England

175. School dental screening programmes for oral health. Full Text available with Trip Pro

School dental screening programmes for oral health. School dental screening refers to visual inspection of children's oral cavity in a school setting followed by making parents aware of their child's current oral health status and treatment needs. Screening at school intends to identify children at an earlier stage than symptomatic disease presentation, hence prompting preventive and therapeutic oral health care for the children. This review evaluates the effectiveness of school dental (...) screening in improving oral health status. It is an update of the original review, which was first published in December 2017.To assess the effectiveness of school dental screening programmes on overall oral health status and use of dental services.Cochrane Oral Health's Information Specialist searched the following databases: Cochrane Oral Health's Trials Register (to 4 March 2019), the Cochrane Central Register of Controlled Trials (CENTRAL, the Cochrane Register of Studies, to 4 March 2019), MEDLINE

2019 Cochrane

176. Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. Full Text available with Trip Pro

Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement. Pancreatic cancer is an uncommon cancer with an age-adjusted annual incidence of 12.9 cases per 100 000 person-years. However, the death rate is 11.0 deaths per 100 000 person-years because the prognosis of pancreatic cancer is poor. Although its incidence is low, pancreatic cancer is the third most common cause of cancer death in the United States. Because of the increasing incidence (...) of pancreatic cancer, along with improvements in early detection and treatment of other types of cancer, it is estimated that pancreatic cancer may soon become the second-leading cause of cancer death in the United States.To update the 2004 US Preventive Services Task Force (USPSTF) recommendation on screening for pancreatic cancer.The USPSTF reviewed the evidence on the benefits and harms of screening for pancreatic cancer, the diagnostic accuracy of screening tests for pancreatic cancer, and the benefits

2019 JAMA

177. External Validation of Two Models to Predict Delirium in Critically Ill Adults Using Either the Confusion Assessment Method-ICU or the Intensive Care Delirium Screening Checklist for Delirium Assessment (Abstract)

External Validation of Two Models to Predict Delirium in Critically Ill Adults Using Either the Confusion Assessment Method-ICU or the Intensive Care Delirium Screening Checklist for Delirium Assessment To externally validate two delirium prediction models (early prediction model for ICU delirium and recalibrated prediction model for ICU delirium) using either the Confusion Assessment Method-ICU or the Intensive Care Delirium Screening Checklist for delirium assessment.Prospective (...) Care Delirium Screening Checklist. Discrimination was determined using the area under the receiver operating characteristic curve. The predictive performance was determined for the Confusion Assessment Method-ICU and Intensive Care Delirium Screening Checklist cohort, and compared with both prediction models' original reported performance. A total of 1,286 Confusion Assessment Method-ICU-assessed patients and 892 Intensive Care Delirium Screening Checklist-assessed patients were included. Compared

2019 EvidenceUpdates

178. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding

Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding - ACOG Menu ▼ Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding Page Navigation ▼ Number 785 Committee on Adolescent Health Care This Committee Opinion was developed by the American College of Obstetricians and Gynecologists’ Committee on Adolescent Health Care (...) in collaboration with committee members Oluyemisi Adeyemi-Fowode, MD and Judith Simms-Cendan, MD. Screening and Management of Bleeding Disorders in Adolescents With Heavy Menstrual Bleeding ABSTRACT : Heavy menstrual bleeding is defined as excessive menstrual blood loss that interferes with a woman's physical, social, emotional, or material quality of life. If obstetrician–gynecologists suspect that a patient has a bleeding disorder, they should work in coordination with a hematologist for laboratory

2019 American College of Obstetricians and Gynecologists

179. Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine)

Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) Screening for dihydropyrimidine dehydrogenase deficiency to decrease the risk of severe toxicities related to fluoropyrimidines (5-fluorouracil or capecitabine) - INAHTA Brief

2019 Haute Autorite de sante

180. What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it?

What is the pathophysiology behind hepatic osteopenia/osteoporosis and who should be screened for it? Chiefs’ Inquiry Corner August 5th, 2019 – Clinical Correlations Search Chiefs’ Inquiry Corner August 5th, 2019 August 5, 2019 2 min read Patients with chronic liver disease are nearly three times more likely to develop osteoporosis than matched controls. In contrast to patients with post-menopausal osteoporosis, in whom increased osteoclast activity depletes bone density, the mechanism (...) in patients with liver disease is thought to be driven by decreased osteoblast activity. Patients with liver disease see decreases in osteoblastogenesis stimulating factors such as IGF-1 and vitamin K and increases in serum bilirubin, which directly inhibits osteoblastogenesis. It is recommended to screen the following female and male patients for hepatic osteopenia: All patients with cirrhosis All patients with chronic cholestasis (bilirubin >3mg/dL for 6 months) All potential liver transplant candidates

2019 Clinical Correlations